Cognition Therapeutics

CGTXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$60.156 M

$0.63 -7.42%

Close of 6 Nov 2026

As of 6 Nov 2026, Cognition Therapeutics (CGTX) has a market capitalization of $60.2M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$23.5M

Loss-making

Shares outstanding

95,100,822

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#118Tenaya TherapeuticsTNYA$72.6M
#119Champions OncologyCSBR$66.7M
#120Cognition TherapeuticsCGTX$60.2M
#121Cardiff OncologyCRDF$58.9M
#122Kalaris TherapeuticsKLRS$55.9M

What if Cognition Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$296,937.23

Per share 469,392× higher

Bitcoin $1.53T

$16,066.76

Per share 25,398× higher

Apple $5.02T

$52,745.66

Per share 83,379× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Cognition Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.